Interim results for BCMA T-cell engager CC-93269 in RRMM

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, presents the interim results of the first clinical study of the bispecific BCMA/CD3 T-cell engager CC-93269 in patients with relapsed/refractory multiple myeloma (CC-93269-MM-001; NCT03486067). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Speaker: Luciano Costa,Event: ASH 2019,Format: Interview,Medicines: CC-93269,Subject: Multiple Myeloma,BCMA,Field: Trial Updates,NCT03486067,Trial: CC-93269-MM-001,CD3,bispecific T-cell engager,CRS,Field: Immuno-Oncology,Medicines: Antibodies,Field: Treatment,